| Literature DB >> 30365357 |
Ilse Gantois1,2, Jelena Popic1,2, Arkady Khoutorsky3, Nahum Sonenberg1,2.
Abstract
Fragile X syndrome (FXS) is the most frequent inherited form of intellectual disability and autism spectrum disorder. Loss of the fragile X mental retardation protein, FMRP, engenders molecular, behavioral, and cognitive deficits in FXS patients. Experiments using different animal models advanced our knowledge of the pathophysiology of FXS and led to the discovery of many targets for drug treatments. In this review, we discuss the potential of metformin, an antidiabetic drug approved by the US Food and Drug Administration, to correct core symptoms of FXS and other neurological disorders in humans. We summarize its mechanisms of action in different animal and cellular models and human diseases.Entities:
Keywords: ERK; autism spectrum disorders; fragile X syndrome; mTOR; metformin; protein synthesis
Mesh:
Substances:
Year: 2018 PMID: 30365357 DOI: 10.1146/annurev-med-081117-041238
Source DB: PubMed Journal: Annu Rev Med ISSN: 0066-4219 Impact factor: 13.739